The Fate and Fortunes of the Lazarus Drug, Part Two
After a near thirty-year effort by it's manufacturer, Hemispherx Biopharma, to achieve Food and Drug Administration approval for Ampligen's use as a first-line therapy for myalgic encephalomyelitis, the drug is all but unavailable in the U.S. to patients. A significant price hike and rigid enforcement of dosing protocols by the company has put the drug out of reach. Even at its height, FDA's stance on the drug made it accessible only to the very rich, or the very desperate. At no time in history has the drug been available to any more than .05 or .1 percent of the ME population. A requiem for Ampligen and its inventor, William Carter.
The Fate and Fortunes of the Lazaurus Drug, Part One
Ampligen is all but unavailable in the United States, but a small group of Canadian patients are seeking to push their government toward approving the drug for what could be an exploding Canadian patient population. An inside look at the first meeting between of Hemispherx executives and Canadian activists to discuss strategy.